Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide in Acute Minor Ischemic Stroke or High-risk TIA with T2DM
NCT03948347Unknown
- Sponsor
- First Affiliated Hospital of Jinan University
- Start
- Jun 2019
- Primary completion
- Dec 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, single-blind trial of liraglutide in ischemic stroke and Transient Ischemic Attack (TIA), sponsored by First Affiliated Hospital of Jinan University. Primary endpoint: Percentage of patients with 90-day new stroke events. Status: unknown.
02
Drugs
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT03948347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03948347.